Supplier log in
Supply of Prostate Cancer Medicines
Details
| RFx ID : | 32362872 |
| Tender Name : | Supply of Prostate Cancer Medicines |
| Reference # : | A1436422 |
| Open Date : | Q3 2025 |
| Indicative RFx Release Date : | Q4 2025 [?] |
| Tender Type : | Future Procurement Opportunity (FPO) |
| Project Status : | Initial development [?] |
| Indicative Total Value : | $50M - $100M [?] |
| Expected number of contracts offered : | 2 |
| Tender Coverage : | Sole Agency [?] |
| Categories : |
|
| Regions: |
|
| Required Pre-qualifications : | None |
| Contact : |
Pharmac Procurement Team procurement@Pharmac.govt.nz . |
Pharmac is planning on issuing a competitive process for the supply of abiraterone acetate and novel androgen receptor inhibitors (ARIs) for the treatment of prostate cancer.
The specific funding scenarios that could arise as an outcome from this competitive process would be made apparent upon release of the RFP.
In the financial year ending 30 June 2025 (2024/25 financial year) ~1000 people received funded abiraterone, with ~500 people initiating treatment. The number of funded abiraterone acetate 250 mg tablets for this period was ~960,000 tablets.
The gross expenditure on abiraterone acetate in the 2024/25 financial year was approximately $34.21 million. A confidential rebate currently applies to abiraterone acetate, which reduces the net expenditure paid by Pharmac. Please note that this indicative value reflects one year of expenditure and does not represent the total value over the full term of any future contract.
As part of this procurement process, Pharmac may consider changes to the current eligibility criteria for abiraterone acetate. Pharmac does not currently fund any novel ARI for the treatment of prostate cancer.
Funding applications for widened access to abiraterone acetate and novel ARIs currently under consideration can be found on the Pharmac application tracker. Links to specific funding proposals under consideration (detailed below) are provided in the attachments.
- Abiraterone widened access - metastatic hormone sensitive prostate cancer
- Apalutamide – metastatic hormone sensitive prostate cancer
- Apalutamide – non-metastatic castration resistant prostate cancer
- Enzalutamide - metastatic castration resistant prostate cancer
- Enzalutamide - metastatic castration resistant prostate cancer contraindicated to abiraterone acetate
- Darolutamide – non-metastatic castration resistant prostate cancer
Please see further advice received from the Cancer Treatments Advisory Committee (CTAC) at is April 2024 meeting that has helped inform the progression of this competitive process.
